199 related articles for article (PubMed ID: 30816279)
21. Replication competent HIV-guided CRISPR screen identifies antiviral factors including targets of the accessory protein Nef.
Prelli Bozzo C; Laliberté A; De Luna A; Pastorio C; Regensburger K; Krebs S; Graf A; Blum H; Volcic M; Sparrer KMJ; Kirchhoff F
Nat Commun; 2024 May; 15(1):3813. PubMed ID: 38714682
[TBL] [Abstract][Full Text] [Related]
22. Filamin A Is Involved in HIV-1 Vpu-mediated Evasion of Host Restriction by Modulating Tetherin Expression.
Dotson D; Woodruff EA; Villalta F; Dong X
J Biol Chem; 2016 Feb; 291(8):4236-46. PubMed ID: 26742839
[TBL] [Abstract][Full Text] [Related]
23. The size and conservation of a coiled-coil structure in the ectodomain of human BST-2/tetherin is dispensable for inhibition of HIV-1 virion release.
Andrew AJ; Berndsen CE; Kao S; Strebel K
J Biol Chem; 2012 Dec; 287(53):44278-88. PubMed ID: 23152502
[TBL] [Abstract][Full Text] [Related]
24. Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter.
Ji H; Jiang Z; Lu P; Ma L; Li C; Pan H; Fu Z; Qu X; Wang P; Deng J; Yang X; Wang J; Zhu H
Mol Ther; 2016 Mar; 24(3):508-21. PubMed ID: 26775808
[TBL] [Abstract][Full Text] [Related]
25. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
26. Targeting human cytomegalovirus IE genes by CRISPR/Cas9 nuclease effectively inhibits viral replication and reactivation.
Xiao J; Deng J; Zhang Q; Ma P; Lv L; Zhang Y; Li C; Zhang Y
Arch Virol; 2020 Aug; 165(8):1827-1835. PubMed ID: 32507978
[TBL] [Abstract][Full Text] [Related]
27. Tetherin restricts direct cell-to-cell infection of HIV-1.
Kuhl BD; Sloan RD; Donahue DA; Bar-Magen T; Liang C; Wainberg MA
Retrovirology; 2010 Dec; 7():115. PubMed ID: 21184674
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of inactive tetherin delGPI mutant inhibits HIV-1 Vpu-mediated antagonism of endogenous tetherin.
Lv M; Wang J; Zhu Y; Wang X; Zuo T; Liu D; Zhang J; Wu J; Zhang H; Kong W; Yu X
FEBS Lett; 2013 Jan; 587(1):37-43. PubMed ID: 23201263
[TBL] [Abstract][Full Text] [Related]
29. Emerging role of the host restriction factor tetherin in viral immune sensing.
Hotter D; Sauter D; Kirchhoff F
J Mol Biol; 2013 Dec; 425(24):4956-64. PubMed ID: 24075872
[TBL] [Abstract][Full Text] [Related]
30. Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities.
Cocka LJ; Bates P
PLoS Pathog; 2012 Sep; 8(9):e1002931. PubMed ID: 23028328
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
[TBL] [Abstract][Full Text] [Related]
32. ATP1B3 Protein Modulates the Restriction of HIV-1 Production and Nuclear Factor κ Light Chain Enhancer of Activated B Cells (NF-κB) Activation by BST-2.
Nishitsuji H; Sugiyama R; Abe M; Takaku H
J Biol Chem; 2016 Feb; 291(9):4754-62. PubMed ID: 26694617
[TBL] [Abstract][Full Text] [Related]
33. CAML does not modulate tetherin-mediated restriction of HIV-1 particle release.
Ali MS; Hammonds J; Ding L; Spearman P
PLoS One; 2010 Feb; 5(2):e9005. PubMed ID: 20126395
[TBL] [Abstract][Full Text] [Related]
34. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
Van Damme N; Goff D; Katsura C; Jorgenson RL; Mitchell R; Johnson MC; Stephens EB; Guatelli J
Cell Host Microbe; 2008 Apr; 3(4):245-52. PubMed ID: 18342597
[TBL] [Abstract][Full Text] [Related]
35. Targeted Chromatinization and Repression of HIV-1 Provirus Transcription with Repurposed CRISPR/Cas9.
Olson A; Basukala B; Lee S; Gagne M; Wong WW; Henderson AJ
Viruses; 2020 Oct; 12(10):. PubMed ID: 33053801
[TBL] [Abstract][Full Text] [Related]
36. A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV.
OhAinle M; Helms L; Vermeire J; Roesch F; Humes D; Basom R; Delrow JJ; Overbaugh J; Emerman M
Elife; 2018 Dec; 7():. PubMed ID: 30520725
[TBL] [Abstract][Full Text] [Related]
37. Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism.
Dufrasne FE; Lombard C; Goubau P; Ruelle J
Viruses; 2016 Oct; 8(10):. PubMed ID: 27754450
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
[TBL] [Abstract][Full Text] [Related]
39. Simian Immunodeficiency Virus SIVgsn-99CM71 Vpu Employs Different Amino Acids To Antagonize Human and Greater Spot-Nosed Monkey BST-2.
Yao W; Strebel K; Yamaoka S; Yoshida T
J Virol; 2022 Feb; 96(4):e0152721. PubMed ID: 34878886
[TBL] [Abstract][Full Text] [Related]
40. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
